You are here

Mace Rothenberg, MD

Co-Chair, Life Sciences Consortium Task Force
Chief Medical Officer, Pfizer

Mace L. Rothenberg, MD, is Chief Medical Officer at Pfizer. He joined Pfizer in 2008 and previously served as Senior Vice President, Head of Clinical Development and Medical Affairs for Pfizer Oncology; Chief Medical Officer for Pfizer Oncology; and Chief Development Officer, Oncology.

Prior to joining Pfizer, Mace was Professor of Medicine at the Vanderbilt University Medical Center and Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center. He was active in clinical-translational research in oncology for more than 20 years. Mace was the recipient of several research grants from the National Cancer Institute and served on several NIH study sections.

Mace has published more than 150 articles and books, primarily in the areas of early stage drug development, gastrointestinal malignancies and ovarian cancer. Mace has served on the editorial boards of several leading medical journals, including the Journal of Clinical Oncology and Clinical Cancer Research. His work was critical to the development and eventual FDA approval of irinotecan (CPT-11, Camptosar®) in 1996 and oxaliplatin (Eloxatin®) in 2002 for colorectal cancer and gemcitabine (Gemzar®) in 1996 for pancreatic cancer. In addition to his clinical research accomplishments, Mace has been recognized for his compassionate care of cancer patients. In 2008, he received the Lane W. Adams Quality of Life Award from the American Cancer Society, honoring him as one of the nation's top cancer caregivers.

Mace received his B.A. from the University of Pennsylvania in 1978 and his M.D. from the New York University School of Medicine in 1982. He trained as an Intern and Resident in Internal Medicine at Vanderbilt University and obtained his medical oncology training at the National Cancer Institute.